International Journal of Web of Multidisciplinary Studies
(Peer-Reviewed, Open Access, Fully Refereed International Journal)
website: https://ijwos.com OPEN ACCESS E-ISSN : 3049-2424
Volume 3 Issue 7 , July 2026
DOI: https://doi.org/10.71366/ijwos03072600847

A Comprehensive Review of Blood Cancer: Classification, Pathogenesis, Diagnostic Methods, and Management Advances

Dr. P. Sri Varsha[1], J. Poojitha[2], T. Varsha[3]
[1] *Assistant Professor, Department of Pharmacy Practice, Malla Reddy College of Pharmacy, Maisammaguda, Dhulapally, Secunderabad, Telangana, India – 500100.*
[2,3] *Pharm.D (Post Baccalaureate), First Year, Malla Reddy College of Pharmacy, Maisammaguda, Dhulapally, Secunderabad, Telangana, India – 500100.*

Article Info

Article History:

Published: 2 July 2026

Publication Issue:
Volume 3, Issue 7
July-2026

Page Number:
1-13

Corresponding Author:
J. Poojitha

Abstract:

Hematological malignancy or blood cancer is a group of cancers that originate in blood-forming tissues like bone marrow and lymphatic system. The three main types of blood cancer are leukemia, lymphoma and multiple myeloma. Blood cancers involve the uncontrolled growth of abnormal blood cells, which interferes with normal blood cell production and immune function. Blood cancer is a major health challenge of the world and the leading contributor to cancer morbidity and mortality worldwide. The development of these malignancies is associated with a combination of genetic , environmental and immunological factors including chromosomal abnormalities , exposure to ionizing radiation and toxic chemicals , viral infections and inherited predisposition . Typical clinical manifestations include fatigue, anemia, recurrent infections, unexplained weight loss, fever, night sweats, lymphadenopathy, and bleeding disorders. Recent advances in diagnostic techniques such as flow cytometry, cytogenetic analysis, molecular testing and next-generation sequencing have enhanced early detection and risk stratification. Treatment strategies have been significantly improved and include chemotherapy, radiotherapy, targeted therapy, immunotherapy and hematopoietic stem cell transplantation. Novel therapeutic strategies, including chimeric antigen receptor T-cell (CAR-T) therapy and precision medicine, have shown promise in patients with resistant or relapsed disease. This review summarizes the classification, epidemiology, etiology, pathophysiology, clinical features, diagnostic approaches, treatment options, and recent advances in the management of blood cancers. Further studies on molecular mechanisms and personalized therapeutic interventions are expected to improve survival rate, reduce treatment related complication and improve the quality of life of affected individuals.

Keywords: Blood Cancer, Hematologic Malignancies, Leukemia, Lymphoma, Multiple Myeloma, Immunotherapy, Targeted Therapy, Stem Cell Transplantation, CAR-T Cell Therapy, Precision Medicine

1. Introduction

Blood cancer or hematological malignancy is a group of malignancies that impair the generation and function of blood cells. These cancers arise mostly in the bone marrow, lymphatic system or blood-forming organs, leading to the uncontrolled production of aberrant blood cells. There are three main types of blood cancer: leukemia, lymphoma and multiple myeloma. These illnesses disrupt normal hematopoiesis, decrease immunological function and may result in life threatening complications if not treated [1].

Blood malignancies are a major public health problem worldwide. Hematological malignancies represent a significant fraction of the new cancer cases and cancer-related deaths per year worldwide. The incidence of blood cancer is on the rise in the last few decades because of the aging population, environmental exposures, greater diagnostic capabilities, and risk factors associated with lifestyle. Leukemia, lymphoma and multiple myeloma represent a large proportion of the global cancer burden, affecting all age groups [2,10].

Early diagnosis and proper treatment are critical in improving patient outcomes and survival rates. The management of blood malignancies has been transformed by advances in molecular diagnostics, targeted medicines, immunotherapy and hematopoietic stem cell transplantation. However, late diagnosis is still a major concern, especially in low- and middle-income countries where access to specialized healthcare services may be limited. Therefore, better awareness, early detection measures and continuous research are needed to reduce the morbidity and mortality associated with these cancers [1,2].

2. Blood Cancer Classification

Blood malignancies are often categorized into three groups, leukemia, lymphoma and multiple myeloma, according on where the cancer cells originate and what they look like.

Leukaemia

Leukemia is a cancer of blood-forming tissues in which the bone marrow and peripheral blood become filled with aberrant white blood cells that do not function properly. Leukemia is divided into acute and chronic types, depending on how quickly it develops and which type of cells are involved[1].

ALL (Acute Lymphoblastic Leukemia)

Acute lymphoblastic leukemia is a neoplasm of immature lymphoid cells (lymphoblasts) that proliferate rapidly . It is the most prevalent children cancer but can also arise in adults. Common symptoms are weariness, fever, recurring infections, tendency to bleed and bone discomfort[4].

Acute Myeloid Leukemia (AML)

Acute myeloid leukemia represents malignant alteration of the myeloid progenitor cells. It is more common among adults and old people. AML is a quickly progressive disease and commonly presents with anemia, thrombocytopenia, neutropenia and bone marrow failure[3,19].

Chronic lymphocytic leukaemia (CLL)

Chronic lymphocytic leukemia is marked by the proliferation of mature, but functionally abnormal, B cells. It is the commonest form of leukemia in adults in the Western world and often follows an indolent clinical course[5].

Chronic myeloid leukaemia (CML)

The Philadelphia chromosome, arising from the t(9;22) chromosomal translocation, is related with chronic myeloid leukemia. This defect leads to development of the BCR-ABL fusion gene, which causes uncontrolled cell proliferation. Tyrosine kinase inhibitors (TKIs) as targeted therapy have greatly improved prognosis of CML patients[6].

Lymphoma

Lymphoma is a malignancy that starts in the lymphatic system when malignant cells grow. It primarily involves lymph nodes and also extranodal tissues[18].

Hodgkin Lymphoma

Hodgkin lymphoma is distinguished by the appearance of Reed-Sternberg cells in the involved lymphoid tissues. It is usually observed in young adults and has a pretty good prognosis with modern methods of treatment[7,14].

Non-Hodgkin's Lymphoma

Non-Hodgkin lymphoma (NHL) is a varied category of lymphoid neoplasms with a broad spectrum of clinical behavior, appearance, and response to treatment. It is more frequent than Hodgkin's disease and ranges from indolent to very aggressive[8].

Myeloma Multiple

Multiple myeloma is a plasma cell cancer defined by the overproduction of aberrant monoclonal immunoglobulins. It is mostly a bone marrow disease linked with bone destruction, anemia, renal failure and recurrent infections. Significant improvements in survival have been seen in recent years in people with multiple myeloma[9].

3. Epidemiologic aspects

Together, blood cancers form a large part of the world's cancer burden. Leukemia, lymphoma, and multiple myeloma are diseases affecting millions of people globally and are a major issue for health care systems. The incidence of hematological malignancies differs across the world due to genetic predisposition, environmental exposures, socio-economic status and access to healthcare[10,12].

Blood malignancies continue to have high mortality despite breakthroughs in diagnosis and treatment. Although the survival rates have been dramatically improved during the last decades, hematological malignancies still constitute a major percentage of the cancer-associated fatalities all over the world. Survival results vary on cancer subtype, age at diagnosis, illness stage, genetic mutations and availability of treatment[2,10].

In the epidemiology of blood malignancies, age and sex are crucial factors. Acute lymphoblastic leukemia is mostly a childhood disease, whereas acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia and multiple myeloma tend to occur more frequently in older persons. Most hematologic malignancies are more common in men than women[12].

Several risk factors have been associated with the development of blood malignancies. These include genetic predisposition, exposure to ionizing radiation, occupational exposure to chemicals such as benzene, cigarette smoking,

viral infections including Epstein-Barr virus and human T-cell leukemia virus type 1, immune dysfunction, autoimmune disorders and previous exposure to chemotherapy or radiotherapy. It is important to identify these risk factors for the development of preventative interventions and improvement of illness outcome[11,12].

4. Causes and Risk Factors.

Blood malignancies arise from a complex interplay of genetic predisposition, environmental exposures, infectious agents, and lifestyle variables. While the specific etiology of many hematological malignancies remains elusive, certain risk factors have been reliably associated with an increased incidence of disease development.

Genetic Factors

Genetic abnormalities are key to the etiology of blood malignancies. Chromosomal translocation, gene mutation, deletion or epigenetic change, or any combination of these, might interfere with normal cell development and differentiation. Mutations of genes like TP53, FLT3, NPM1, JAK2 and BCR-ABL have been associated with several hematological cancers. Inherited genetic disorders, including Down syndrome, Fanconi anemia, Bloom syndrome, and Li-Fraumeni syndrome, are connected with an increased risk of acquiring leukemia and lymphoma[13].

Radiation Dose

Radiation is a known risk factor for blood malignancies . Increased incidence of leukemia and other hematological malignancies has been seen in survivors of atomic bomb detonation and persons subjected to therapeutic radiation. Radiation causes DNA damage, chromosomal instability and mutations that results in malignant transformation of hematopoietic cells[12].

Chemical exposures

Workplace and environmental exposure to chemicals such as benzene, insecticides, formaldehyde and industrial solvents have been associated with an elevated risk of blood malignancies. Benzene is known to be a potent hematotoxic and carcinogenic substance that can cause bone marrow suppression and genetic changes that lead to leukemogenesis[11].

Tobacco

Cigarette smoking has been connected with increased risk of numerous hematological malignancies, especially acute myeloid leukemia. Tobacco smoke contains many carcinogens that can damage DNA and cause mutation in hematopoietic stem cells[12].

Viral Diseases

Certain viral infections play a major role in the development of blood malignancies. Hodgkin lymphoma, Burkitt lymphoma and post-transplant lymphoproliferative diseases are all highly related with Epstein-Barr virus (EBV). Human immunodeficiency virus (HIV) predisposes to malignant lymphomas via immunological suppression. Human T-cell leukemia virus type-1 (HTLV-1) is the causal agent of adult T-cell leukemia/lymphoma[14].

Family history

Hematologic cancers occur with greater frequency in people with a family history of leukemia, lymphoma, or multiple myeloma. Familial clustering suggests the involvement of inherited genetic susceptibility and shared environmental variables in illness development[13].

5. Pathophysiology

Blood malignancies are caused by malignant alteration of hematopoietic cells, leading to uncontrolled proliferation, poor differentiation and resistance to apoptosis. Pathophysiology is a complex interaction of genetic, molecular and cellular disorders which affect normal hematopoiesis and immunological control.

Normal Hematopoiesis

Hematopoiesis is the process of formation of blood cellular components (erythrocytes, leukocytes, and platelets) from hematopoietic stem cells (HSCs) in the bone marrow. This highly regulated process is governed by growth factors, cytokines, transcription factors and signaling pathways that maintain cellular homeostasis and regular blood cell formation[15].

Genetic Mutations Involved

Many genetic changes found in blood malignancies. Typical for chronic myeloid leukaemia are chromosomal translocations, e.g. t(9;22) resulting in the BCR-ABL fusion gene. Abnormal cell proliferation and survival is caused by changes in FLT3, NPM1, DNMT3A, IDH1, IDH2, TP53, and JAK2. These genetic disorders affect signaling pathways involved in cell cycle progression, apoptosis, DNA repair and differentiation.

Mechanism of Malignant Transformation

Hematopoietic stem or progenitor cells acquire genetic and epigenetic defects that endow them with growth benefits resulting in malignant transformation. These changes cause unregulated cell division, aberrant cell maturation, decreased apoptosis and a buildup of dysfunctional blood cells. The increasing malignant clone gradually replaces normal elements of bone marrow resulting in inefficient hematopoiesis and inhibition of proper blood cell formation. Moreover, interactions between malignant cells and bone marrow microenvironment mediate tumor survival, immune evasion and disease development[1,23].

6. Clinical Presentation

The clinical picture of blood malignancies depends on the kind and stage of the disease. However, many of the signs are due to bone marrow loss, immunological dysfunction and infiltration of malignant cells in numerous organs.

Anemia

Anemia is a frequent presentation because to reduced red blood cell production from marrow invasion. Patients often have pallor, weakness, shortness of breath, and impaired exercise tolerance.

Tiredness

Persistent weariness is a common sign of blood malignancies. It arises from anemia, increased metabolic requirements of malignant cells, and systemic inflammatory reactions.

Fever

Unexplained fever may be caused to illnesses associated with immune suppression or may be a direct effect of cytokine release from malignant cells.

Losing weight

Unintentional weight loss is a frequent constitutional symptom seen in association with increased metabolic activity, chronic inflammation and illness development.

Sweats (Night)

Profuse night sweats are often found in patients with lymphoma and leukemia and are regarded as one of the hallmark "B symptoms" of hematological malignancies.

Recurrent infections

Immune defects and abnormal white cell activity predispose to recurrent bacterial, viral and fungal infections.

Bleeding and Bruising

Thrombocytopenia due to bone marrow failure may cause easy bruising, petechiae, delayed bleeding time, epistaxis and gingival hemorrhage.

lymphadenopathy

Swelling of lymph nodes is a hallmark of many leukemias and lymphomas. Patients may appear with painless swelling of cervical, axillary, mediastinal or inguinal lymph nodes[3,9,7,8].

7. Diagnostic Techniques

Accurate diagnosis of blood malignancies is critical to identify the type of disease, its stage, prognosis and the suitable treatment strategy. The diagnosis of hematological malignancies relies on a mix of clinical examination, laboratory investigations, morphological assessment, immunophenotyping, cytogenetic studies, molecular testing and imaging techniques. Recent developments in diagnostic technologies have greatly enhanced the precision of disease classification and risk stratification[1,16].

Complete Blood Count (CBC)

When blood cancer is suspected, a Complete Blood Count (CBC) is generally the first lab test ordered. It provides the quantitative information about red blood cells, white blood cells, hemoglobin, hematocrit and platelet counts. Abnormal Findings Leukocytosis Leukopenia Anemia Thrombocytopenia Thrombocytosis In leukemia, you may have too many or too few white blood cells. You also may have immature cells called blasts. CBC findings are an important screening tool and lead additional diagnostic tests[16].

Blood Smear

Peripheral blood smear examination is the microscopic analysis of dyed blood samples to evaluate the morphology and distribution of blood cells. This approach can detect aberrant leukocytes, blast cells, dysplastic characteristics and other hematological abnormalities that are indicative of cancer. The presence of circulating blasts, aberrant lymphocytes, smudge cells or abnormal plasma cells can provide important clues to specific hematologic diseases. Peripheral smear examination is one of the cost effective and critical part of diagnosis of blood cancer[15].

Bone Marrow Biopsy

Bone marrow aspiration and biopsy are regarded the gold standard methods for the diagnosis of several hematological malignancies. Bone marrow examination offers direct evaluation of cellularity, morphology, blast proportion, infiltration patterns and disease load. It is important for diagnosis and categorization of leukemia, lymphoma involving the marrow, multiple myeloma and myelodysplastic disorders. Histopathological assessment also assists in assessing response to treatment and disease progression[19].

Flow cytometry analysis

Flow cytometry is a highly sensitive immunophenotyping technology that identifies and characterizes cell types based on their surface and intracellular markers. This technique is commonly used in diagnosis of leukemia, lymphoma and multiple myeloma, and permits discrimination of normal and malignant hematopoietic cells. Flow cytometry gives information on lineage determination, illness categorization, prognostic indicators and minimal residual disease detection, thereby contributing greatly to patient treatment[17].

Cytogenetic Study

Cytogenetic examinations are used to assess chromosomal abnormalities linked with hematological malignancies. Conventional karyotyping and fluorescence in situ hybridization (FISH) identify structural and numerical chromosomal abnormalities, respectively. Characteristic abnormalities include the Philadelphia chromosome [t(9;22)] in chronic myeloid leukemia, t(15;17) in acute promyelocytic leukemia and the variety of translocations seen in lymphomas. These are critical for diagnosis and prognosis. Cytogenetic data frequently guide treatment selection and risk classification[18].

Molecular diagnostic Molecular diagnostic techniques have improved the diagnosis and therapy of hematological malignancies. Techniques like polymerase chain reaction (PCR), reverse transcription-PCR, next generation sequencing (NGS) and gene expression profiling allow the detection of specific genetic mutations and molecular disorders. FLT3, NPM1, TP53, IDH1, IDH2, JAK2 and BCR-ABL are often examined mutations in clinical practice. Molecular testing is helpful for early diagnosis, prognosis assessment, therapeutic decision making, and monitoring of treatment response[22,23].

Imaging Methods

Imaging scans are often used to assess degree of disease, organ involvement and response to treatment in patients with haematological malignancies. Computed tomography (CT) scans are often used to assess lymph node enlargement and extranodal illness. Positron emission tomography with computed tomography (PET-CT) is particularly helpful in staging and monitoring Hodgkin lymphoma and aggressive non-Hodgkin lymphomas. Central nervous system involvement, bone marrow infiltration and soft tissue lesions can be evaluated by magnetic resonance imaging (MRI). Imaging techniques provide a thorough assessment of the illness distribution and course, in addition to laboratory and pathological studies[21].

The combination of these diagnostic techniques allows for precise categorization, staging, prognostic assessment, and individualized treatment of hematologic malignancies, ultimately improving clinical outcomes and survival rates.

8.Treatment Strategies

The treatment of blood malignancies has changed dramatically in the last few decades due to developments in molecular biology, immunology and precision medicine. The choice of treatment relies on the kind of hematological malignancy, stage of disease, genetic anomalies, age of patient, comorbidities and overall performance level. Current therapeutic techniques include chemotherapy, radiation, targeted therapy, immunotherapy and hematopoietic stem cell transplantation.

8.1 Chemotherapy

Chemotherapy is still one of the most extensively utilized treatment techniques for blood malignancies. It involves the use of cytotoxic medicines which target quickly dividing cancer cells. Chemotherapy may be employed as induction, consolidation, maintenance, or salvage therapy, depending on the disease subtype. Commonly utilized agents are cyclophosphamide, cytarabine, vincristine, doxorubicin, methotrexate, and prednisone. Chemotherapy can cause remission and prolong survival, but is commonly associated with side effects such as myelosuppression, nausea, vomiting, alopecia and increased risk of infections[24].

8.2 Radiation therapy

Radiotherapy employs high energy radiation to eliminate the malignant cells and decrease tumor burden. It is particularly effective in localised lymphomas , palliation of symptomatic lesions and conditioning regimens before stem cell transplantation . Radiation therapy may also be used in treating central nervous system involvement and bulky lymph node disease. Improvements in the administration of radiation have allowed for more precise treatments with less damage to the nearby healthy tissues[24].

8.3 Targeted Therapies

Targeted therapies specifically block molecular pathways involved in cancer formation and progression, thereby enhancing efficacy and minimizing toxicity compared with standard chemotherapy.

Imatinib

Imatinib is a tyrosine kinase inhibitor that targets the BCR-ABL fusion protein, which is associated with chronic myeloid leukemia. Imatinib has changed the survival outcomes and for many patients CML is now a chronic condition that may be managed[6].

Rituximab

Rituximab is a monoclonal antibody against the CD20 antigen expressed on B cells. It is a commonly used in the management of B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia, either alone or in combination with chemotherapy[8].

BTK Inhibitors

Bruton's tyrosine kinase (BTK) inhibitors such as ibrutinib, acalabrutinib and zanubrutinib have become successful therapy for chronic lymphocytic leukemia, mantle cell lymphoma and other B-cell cancers. These drugs interfere with B-cell receptor signaling pathways and induce death of cancer cells[27].

8.4 Immunotherapy

Immunotherapy boosts the immune system’s ability to fight malignant cells and has changed the face of blood cancer treatment.

Monoclonal antibody

Monoclonal antibodies bind to particular antigens on cancer cells. Examples include rituximab (CD20), daratumumab (CD38) and brentuximab vedotin (CD30). They mediate tumor cell death via immune-mediated pathways and direct cytotoxic actions.

CAR-T Cell Therapy

Chimeric Antigen Receptor T-cell (CAR-T) treatment is a novel method of adoptive cellular immunotherapy. Patient T cells are genetically engineered to express receptors that identify tumor specific antigens, such as CD19. CAR-T treatment has shown spectacular results in relapsed or refractory B-cell leukemias and lymphomas with long-term remission in select patients[24-26].

8.5 Hematopoietic stem cell transplant

Hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment option for a variety of hematologic malignancies. The process involves replacing damaged bone marrow with healthy hematopoietic stem cells from the patient (autologous transplant) , or from a donor (allogeneic transplant) . HSCT is frequently employed for patients with leukemia, lymphoma and multiple myeloma, especially those who are at high risk or have relapsed disease.

9. Recent Progress in Blood Cancer Management

Advancements in technology and science have greatly enhanced the ability to diagnose and cure blood malignancies in recent times.

Personalized Medicine

Precision medicine employs genetic, molecular, and clinical data to personalize treatment regimens for unique patient profiles. This method boosts therapeutic efficacy and reduces side effects.

Gene Therapy

Gene therapy is intended to repair or change bad genes that cause cancer. New gene-editing tools, such as CRISPR-Cas9, have showed promise in targeting the genetic anomalies associated with blood cancers.

New biomarkers

Recent progress in molecular biology has led to the development of novel biomarkers useful for diagnosis, prognosis, disease monitoring and therapy selection. Minimal residual disease (MRD), circulating tumor DNA and particular gene alterations are more and more used in clinical practice.

Artificial Intelligence in Diagnosis

Artificial intelligence (AI) and machine learning algorithms are being integrated into hematology for automated picture interpretation, diagnostic prediction, risk stratification and treatment planning. AI solutions have the ability to increase the accuracy of diagnosis and minimize the workload in healthcare.

Emerging Drugs

Several innovative therapeutic treatments are under development, including bispecific antibodies, antibody-drug conjugates, immune checkpoint inhibitors, selective kinase inhibitors and next-generation cellular therapies. The agents are constantly increasing the therapeutic choices for patients with resistant or relapsing illness[27,28].

10. Complications and Prognosis Complications of Disease

Blood malignancies can lead to a variety of consequences such as severe anemia, recurrent infections, thrombocytopenia, bleeding disorders, infiltration of organs, deterioration of bones, hypercalcemia and renal impairment. Advanced illness can lead to considerable morbidity and decreased quality of life.

Complications Related to Treatment

Therapeutic interventions may be accompanied with side consequences including myelosuppression, immunosuppression, secondary malignancies, graft-versus-host disease, cardiotoxicity, neurotoxicity and treatment-related infections. Therefore, there is a need for long-term monitoring.

Survival Results

Survival outcomes differ greatly depending on cancer kind, genetic mutations, stage upon diagnosis, patient age, and therapy response. Survival rates of many hematological malignancies have dramatically improved with the advent of targeted medicines, immunotherapy, and stem cell transplantation[2,9,24].

11. Prevention and Early Detection Strategies for Risk Reduction

Many blood cancers are not totally preventable , however risk reduction may involve avoidance of tobacco use , decrease of exposure to ionizing radiation and harmful chemicals , good lifestyle choices and occupational safety .

Screening Strategies

Unlike some solid tumors, there are no standard population-wide screening programs for blood malignancies. But regular check-ups, blood counts and surveillance of high-risk patients may be able to help diagnose it early.

Public Information

Public education regarding symptoms of severe weariness, weight loss, frequent infections, unusual bleeding and swelling of the lymph nodes can encourage early medical attention and diagnosis[11,12,2,16].

12. Future prospectives

Current Clinical Trials

A large number of clinical trials are testing next-generation immunotherapies, targeted therapeutics, bispecific antibodies, CAR-T cell products, and combination treatment regimens with the goal of improving patient outcomes.

Personalised Medicine

The future treatment options are predicted to be more and more dependent on tailored therapeutic approaches based on genetic profiling, molecular markers and patient specific illness characteristics.

Research Gaps

Despite tremendous progress, obstacles remain in the domains of treatment resistance, recurrence, control of toxicity, access to healthcare and the discovery of reliable prognostic biomarkers. Further study is necessary to overcome these constraints and improve long-term outcomes[25,26,28].

13. Conclusions

Blood cancers are a broad group of hematologic malignancies and represent a major worldwide health challenge. Significant advances in our understanding of disease biology have led to major advancements in diagnosis, risk classification and treatment. The emergence of targeted medicines, immunotherapy, CAR-T cell therapy and stem cell transplantation has changed the way patients are managed and has resulted in better survival rates. Nevertheless, problems of treatment resistance, relapse, side effects, and healthcare inequalities persist. Additional research into precision medicine, novel biomarkers, gene therapy, and new therapeutic strategies are required to improve patient outcomes and quality of life. Early detection, public awareness and multidisciplinary care remain key components to reduce the incidence of blood malignancies worldwide.

References

1. Arber DA, Orazi A, Hasserjian RP, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2022 WHO classification of hematolymphoid tumors. Leukemia. 2022;36(7):1703-1719.

2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):17-48.

3. Khwaja A, Bjorkholm M, Gale RE, Levine RL, Jordan CT, Ehninger G, et al. Acute myeloid leukaemia. Nat Rev Dis Primers. 2016;2:16010.

4. Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and update. Blood Cancer J. 2017;7(6).

5. Hallek M. Chronic lymphocytic leukemia: 2024 update on diagnosis, risk stratification and treatment. Am J Hematol. 2024;99(1):4-25.

6. Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917-927.

7. Ansell SM. Hodgkin lymphoma: diagnosis and treatment. Mayo Clin Proc. 2015;90(11):1574-1583. 8.Armitage JO, Gascoyne RD, Lunning MA, Cavalli F. Non-Hodgkin lymphoma. Lancet. 2017;390(10091):298-310.

9. Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024;99(2):280-301.

10. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide. CA Cancer J Clin. 2024.

11. Smith MT. Advances in understanding benzene health effects and susceptibility. Annu Rev Public Health. 2010;31:133-148.

12. Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 2019;36:70-87.

13. Taylor GM. Family history and inherited predisposition to hematological malignancies. Blood Rev. 2021;46:100740.

14. Küppers R. The biology of Hodgkin lymphoma. Nat Rev Cancer. 2009;9(1):15-27.

15. Bain BJ. Blood Cells: A Practical Guide. 6th ed. Oxford: Wiley-Blackwell; 2021.

16. McPherson RA, Pincus MR. Henry's Clinical Diagnosis and Management by Laboratory Methods. 25th ed. St. Louis: Elsevier; 2022.

17. Borowitz MJ, Bene MC, Harris NL, Porwit A, Matutes E. Flow cytometry in the diagnosis and monitoring of hematologic neoplasms. Blood. 2019;134(1):4-13.

18. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed. Lyon: IARC Press; 2017.

19. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of acute myeloid leukemia in adults. Blood. 2017;129(4):424-447.

20. Heuser M, Ofran Y, Boissel N, Brunet Mauri S, Craddock C, Janssen J, et al. Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2022;33(12):129-145.

21. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma. J Clin Oncol. 2014;32(27):3059-3068.

22. Metzker ML. Sequencing technologies—the next generation. Nat Rev Genet. 2010;11(1):31-46.

23. Grimwade D, Ivey A, Huntly BJP. Molecular landscape of acute myeloid leukemia and its clinical significance. Blood. 2016;127(1):29-41.

24. DeVita VT, Lawrence TS, Rosenberg SA. DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. 12th ed. Philadelphia: Wolters Kluwer; 2023.

25. June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379(1):64-73.

26. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR-T cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531-2544.

27. Frampton JE. Zanubrutinib: a review in B-cell malignancies. Drugs. 2023;83(2):201-213.

28. Short NJ, Kantarjian H, Jabbour E. Precision medicine in acute leukemia. Clin Cancer Res. 2022;28(11):2164-2174.